tiprankstipranks
Trending News
More News >
Johnson & Johnson (JNJ)
NYSE:JNJ

Johnson & Johnson (JNJ) Price & Analysis

Compare
26,131 Followers

JNJ Stock Chart & Stats


---

Bulls Say, Bears Say

Bulls Say
Acquisition StrategyThe company has a strong track record of augmenting revenue growth in the Innovative Medicines business via acquisitions.
Revenue GrowthTotal revenue estimates for 2025 are 2% higher due to the acquisition of Caplyta from ITCI and favorable foreign exchange rates.
Bears Say
CompetitionThere are concerns about the ability of the MedTech business to compete for the capital required to execute its strategy.
EarningsThe price objective was lowered to $159 from $171 due to new, lower 2025 EPS estimates.
Legal ChallengesCourt rejection of JNJ’s prepackaged bankruptcy proposal due to voting irregularities and the judge's decision to not release future lawsuits against retailers.
Litigation UncertaintyThe rejection of JNJ's third bankruptcy proposal increases uncertainty of cost and outcome and likely prolongs the litigation timeline.
---

Financials

Quarterly

Ownership Overview

0.04%18.79%14.38%45.36%
14.38% Other Institutional Investors
45.36% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

JNJ FAQ

What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $140.68 and its highest was $169.99 in the past 12 months.
    What is Johnson & Johnson’s market cap?
    Johnson & Johnson’s market cap is $371.98B.
      When is Johnson & Johnson’s upcoming earnings report date?
      Johnson & Johnson’s upcoming earnings report date is Apr 15, 2025 which is today.
        How were Johnson & Johnson’s earnings last quarter?
        Johnson & Johnson released its earnings results on Jan 22, 2025. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.992 by $0.048.
          Is Johnson & Johnson overvalued?
          According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Johnson & Johnson pay dividends?
            Johnson & Johnson pays a Quarterly dividend of $1.24 which represents an annual dividend yield of 3.27%. See more information on Johnson & Johnson dividends here
              What is Johnson & Johnson’s EPS estimate?
              Johnson & Johnson’s EPS estimate is 2.58.
                How many shares outstanding does Johnson & Johnson have?
                Johnson & Johnson has 2,409,847,700 shares outstanding.
                  What happened to Johnson & Johnson’s price movement after its last earnings report?
                  Johnson & Johnson reported an EPS of $2.04 in its last earnings report, beating expectations of $1.992. Following the earnings report the stock price went down -1.939%.
                    Which hedge fund is a major shareholder of Johnson & Johnson?
                    Currently, no hedge funds are holding shares in JNJ
                    ---

                    Company Description

                    Johnson & Johnson

                    Johnson & Johnson is a multinational corporation that operates in the healthcare sector, providing a wide range of products and services across its three primary segments: Consumer Health, Pharmaceutical, and Medical Devices. The company's Consumer Health division offers well-known brands in baby care, skin and hair care, wound care, and over-the-counter pharmaceutical products. Its Pharmaceutical segment focuses on manufacturing and marketing a broad portfolio of medications, targeting areas such as immunology, oncology, neurology, and infectious diseases. The Medical Devices segment provides products used in orthopedic, surgery, vision, and cardiovascular fields. Established in 1886, Johnson & Johnson is headquartered in New Brunswick, New Jersey, and is recognized globally for its commitment to improving health and well-being.
                    ---

                    JNJ Company Deck

                    ---

                    JNJ Earnings Call

                    Q4 2025
                    0:00 / 0:00
                    Earnings Call Sentiment|Neutral
                    Johnson & Johnson showed robust growth in sales and innovation in 2024, particularly in the Innovative Medicine and MedTech sectors. However, earnings were negatively impacted by STELARA biosimilars and recent acquisitions, while challenges in China and decreased margins were noted.Read More>
                    ---

                    JNJ Sales Breakdown

                    64.13%64.13%35.87%
                    64.13% Innovative Medicine
                    35.87% MedTech
                    tipranks
                    ---

                    JNJ Stock 12 Month Forecast

                    Average Price Target

                    $168.79
                    ▲(9.35% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"142":"$142","153":"$153","164":"$164","175":"$175","186":"$186"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$185.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":168.79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$168.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$155.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[142,153,164,175,186],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"Apr<br/>2025","25":"Apr<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,153.25,155.69230769230768,158.1346153846154,160.57692307692307,163.01923076923077,165.46153846153845,167.90384615384616,170.34615384615384,172.78846153846155,175.23076923076923,177.67307692307693,180.1153846153846,182.55769230769232,{"y":185,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,153.25,154.44538461538463,155.64076923076922,156.83615384615385,158.03153846153845,159.22692307692307,160.4223076923077,161.6176923076923,162.81307692307692,164.00846153846155,165.20384615384614,166.39923076923077,167.59461538461537,{"y":168.79,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,153.25,153.3846153846154,153.51923076923077,153.65384615384616,153.78846153846155,153.92307692307693,154.05769230769232,154.19230769230768,154.32692307692307,154.46153846153845,154.59615384615384,154.73076923076923,154.8653846153846,{"y":155,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":152.88,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.48,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.26,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.04,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157.02,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.42,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157.59,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.47,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.94,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Amgen
                    AstraZeneca
                    Merck & Company
                    Pfizer
                    AbbVie

                    Best Analysts Covering JNJ

                    1 Year
                    1 Year Success Rate
                    23/24 ratings generated profit
                    96%
                    1 Year Average Return
                    +8.98%
                    reiterated a buy rating 15 days ago
                    Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 95.83% of your transactions generating a profit, with an average return of +8.98% per trade.
                    Popular Stocks
                    ---
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis